Pfizer (PFE) stock in focus as Sally Susman, the company's Chief Corporate Affairs Officer, plans to depart after 18 years.

Changing market conditions and consumer tastes and preferences have weighed on these businesses. Investors can learn a lot ...

One of the best known communications executives in corporate America, Susman worked at Pfizer for nearly two decades after ...

According to Bloomberg, citing an email sent by Chief Executive Officer Albert Bourla on Tuesday, Susman’s responsibilities ...

Discover why options trading trends, robust R&D, and strong free cash flow position Pfizer Inc. for growth. Click for my ...

At recent prices, the yield you receive from Pfizer is more than four times the amount you'd receive from the average ...

The Justice Department changed its policy on foreign corruption cases, which might have put an end to investigations into the ...

Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

Pfizer chief corporate affairs officer Sally Susman is departing the company after roughly two decades, CEO Albert Bourla ...

The House Judiciary Committee has subpoenaed a former Pfizer executive who is considered central to its investigation into an ...

PFE's robust late-stage pipeline, recent FDA wins and deep oncology bets position it for long-term growth through 2030.

Achieve Life Sciences has signed up Omnicom to support the launch of nicotine dependence treatment cytisinicline, positioning ...